Sequential blinded treatment decisions in ALK-positive non-small cell lung cancers in the era of precision medicine.
ALK
Liquid biopsy
Next-generation
Non-small cell lung cancer
Sequential treatment
Journal
Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico
ISSN: 1699-3055
Titre abrégé: Clin Transl Oncol
Pays: Italy
ID NLM: 101247119
Informations de publication
Date de publication:
Sep 2020
Sep 2020
Historique:
received:
16
12
2019
accepted:
03
01
2020
pubmed:
20
1
2020
medline:
29
6
2021
entrez:
20
1
2020
Statut:
ppublish
Résumé
Next-generation ALK TKIs have become the new standard of care in first-line setting in advanced ALK-positive NSCLC patients. However, sequential strategies at progression are relevant, as may have an impact on patients' outcome. In this commentary we discuss whether genomic-tailored strategies at progression would be more suitable for improving outcome of ALK-positive NSCLC patients.
Identifiants
pubmed: 31955355
doi: 10.1007/s12094-020-02290-1
pii: 10.1007/s12094-020-02290-1
doi:
Substances chimiques
Protein Kinase Inhibitors
0
ALK protein, human
EC 2.7.10.1
Anaplastic Lymphoma Kinase
EC 2.7.10.1
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM